Veradermics (MANE) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Veradermics is the larger company by market cap ($5.31 billion vs $5.20 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MANE | PTCT |
|---|---|---|
| Share price | $127.19 | $62.35 |
| Market cap | $5.31B | $5.20B |
| 1-day change | +14.64% | -1.39% |
| YTD return | — | -16.76% |
| 1-year return | — | -1.06% |
| 5-year return | — | +66.00% |
| Forward P/E | — | 23.29 |
| EPS (TTM) | $-4.24 | $-0.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.73B |
| Revenue growth (YoY) | — | +114.51% |
| Net income (latest FY) | $-70.00M | $682.64M |
| Operating margin | — | 50.09% |
| Net margin | — | 39.44% |
| 52-week high | $136.72 | $90.87 |
| 52-week low | $32.00 | $61.23 |
| Distance from 52-week high | -6.97% | -31.39% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +28.55% | +63.26% |
| Average volume | 729.81K | 1.14M |
| Shares outstanding | 41.78M | 83.46M |
| Employees | 37 | 991 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
MANE vs PTCT FAQ
Which is bigger, Veradermics or PTC Therapeutics?
Veradermics (MANE) is larger, with a market capitalization of $5.31B compared with $5.20B for PTC Therapeutics (PTCT).
Are Veradermics and PTC Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.